<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Chemotherapy for advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> leads to improved survival; however, predictors of response to systemic treatment are not available </plain></SENT>
<SENT sid="1" pm="."><plain>Genomic and epigenetic alterations of the gene encoding transcription factor AP-2 epsilon (TFAP2E) are common in human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The gene encoding dickkopf homolog 4 protein (DKK4) is a potential downstream target of TFAP2E and has been implicated in chemotherapy resistance </plain></SENT>
<SENT sid="3" pm="."><plain>We aimed to further evaluate the role of TFAP2E and DKK4 as predictors of the response of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> to chemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We analyzed the expression, methylation, and function of TFAP2E in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal-cancer</z:e> cell lines in vitro and in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>We examined an initial cohort of 74 patients, followed by four cohorts of patients (total, 220) undergoing chemotherapy or <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: TFAP2E was hypermethylated in 38 of 74 patients (51%) in the initial cohort </plain></SENT>
<SENT sid="7" pm="."><plain>Hypermethylation was associated with decreased expression of TFAP2E in primary and <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal-cancer</z:e> specimens and cell lines </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal-cancer</z:e> cell lines overexpressing DKK4 showed increased chemoresistance to fluorouracil but not irinotecan or <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>In the four other patient cohorts, TFAP2E hypermethylation was significantly associated with nonresponse to chemotherapy (P&lt;0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>Conversely, the probability of response among patients with hypomethylation was approximately six times that in the entire population (overall estimated risk ratio, 5.74; 95% confidence interval, 3.36 to 9.79) </plain></SENT>
<SENT sid="11" pm="."><plain>Epigenetic alterations of TFAP2E were independent of mutations in key regulatory <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> genes, microsatellite instability, and other genes that affect fluorouracil metabolism </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: TFAP2E hypermethylation is associated with clinical nonresponsiveness to chemotherapy in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Functional assays confirm that TFAP2E-dependent resistance is mediated through DKK4 </plain></SENT>
<SENT sid="14" pm="."><plain>In patients who have <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> with TFAP2E hypermethylation, targeting of DKK4 may be an option to overcome TFAP2E-mediated drug resistance </plain></SENT>
<SENT sid="15" pm="."><plain>(Funded by Deutsche Forschungsgemeinschaft and others.) </plain></SENT>
</text></document>